Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection
Authors:
- M. RugeMRM. Ruge
- H. TreuerHTH. Treuer
- V. SturmVSV. Sturm
- J. VogesJVJ. Voges
- 25 August 2011
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (10) , 1133-1142
Abstract
The purpose of this study was to assess the impact of stereotactic brachytherapy (SBT) on survival time and outcome when applied after resection of low-grade glioma (LGG) of World Health Organization grade II. From January 1982 through December 2006 we treated 1024 patients who had glioma with stereotactic implantation of iodine-125 seeds and SBT in accordance with a prospective protocol. For the present analysis, we selected 95 of 277 patients with LGG, in whom SBT was applied to treat progressive (43 patients) or recurrent (52 patients) tumor after resection. At 24 months after seed implantation, the tumor response rate was 35.9%, and the tumor control rate was 97.3%. The median progression-free-survival (PFS) duration after SBT was 52.7 ± 7.1 months. Five-year and 10-year PFS probabilities were 43.4% and 10.7%, respectively. Malignant tumor transformation, the diagnosis "astrocytoma," and tumor volume >20 mL were significantly associated with reduced PFS. Tumor progression or relapse after SBT (53 of 95 patients) was treated with tumor resection, a second SBT, chemotherapy, and/or radiotherapy. The median overall survival duration (from the first diagnosis of LGG until the patient's last contact) was 245.0 ± 4.9 months. Patients still under observation after seed implantation had a median follow-up time of 156.4 ± 55.7 months. Perioperative transient morbidity was 1.1%, and the frequency of permanent morbidity caused by SBT was 3.3%. In conclusion, SBT of recurrent or progressive LGG after resection located in functionally critical brain areas has high local efficacy and comparably low morbidity. Referred to individually adopted glioma treatment concepts SBT provides a reasonably long PFS, thus improving overall survival. In selected patients, SBT can lead to delays in the application of chemotherapy and/or radiotherapy.Keywords
This publication has 29 references indexed in Scilit:
- Interstitial125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adultsCancer, 2006
- Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted AgentsThe Oncologist, 2006
- Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidanceCancer, 2005
- Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844)European Journal of Cancer, 1998
- Interstitial radiosurgery of low-grade gliomasJournal of Neurosurgery, 1995
- Recovery of motor function after stroke.Stroke, 1988
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988
- The effect of 125I interstitial radiotherapy on blood-brain barrier function in normal canine brainJournal of Neurosurgery, 1987
- Sequential Morphological Changes in the Dog Brain after Interstitial Iodine-125 IrradiationNeurosurgery, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958